ATE304528T1 - Verbindungen mit wachstumshormon-freisetzenden eigenschaften - Google Patents
Verbindungen mit wachstumshormon-freisetzenden eigenschaftenInfo
- Publication number
- ATE304528T1 ATE304528T1 AT01123155T AT01123155T ATE304528T1 AT E304528 T1 ATE304528 T1 AT E304528T1 AT 01123155 T AT01123155 T AT 01123155T AT 01123155 T AT01123155 T AT 01123155T AT E304528 T1 ATE304528 T1 AT E304528T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- growth hormone
- hormone releasing
- releasing properties
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- 230000003578 releasing effect Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002268 wool Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK80396 | 1996-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE304528T1 true ATE304528T1 (de) | 2005-09-15 |
Family
ID=8097747
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97930368T ATE218537T1 (de) | 1996-07-22 | 1997-07-17 | Verbindungen mit wachstumshormon freisetzenden eigenschaften |
AT01123155T ATE304528T1 (de) | 1996-07-22 | 1997-07-17 | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97930368T ATE218537T1 (de) | 1996-07-22 | 1997-07-17 | Verbindungen mit wachstumshormon freisetzenden eigenschaften |
Country Status (8)
Country | Link |
---|---|
US (3) | US5922770A (fr) |
EP (2) | EP0923539B1 (fr) |
JP (1) | JP4425992B2 (fr) |
AT (2) | ATE218537T1 (fr) |
AU (1) | AU3434697A (fr) |
DE (2) | DE69713109T2 (fr) |
WO (1) | WO1998003473A1 (fr) |
ZA (1) | ZA976371B (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058950A1 (fr) * | 1997-06-20 | 1998-12-30 | Novo Nordisk A/S | Composes ayant des proprietes de liberation de l'hormone de croissance |
US6127341A (en) * | 1997-06-20 | 2000-10-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
PL194560B1 (pl) * | 1998-05-11 | 2007-06-29 | Novo Nordisk As | Związki o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
TW450954B (en) * | 1998-05-14 | 2001-08-21 | Pharmacia & Amp Upjohn Company | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
DE69943239D1 (de) * | 1998-06-30 | 2011-04-14 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
US6919315B1 (en) | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
CN1157224C (zh) | 1999-02-18 | 2004-07-14 | 科研制药株式会社 | 用作生长激素促分泌剂的新酰胺衍生物 |
UA73530C2 (uk) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
CA2401749A1 (fr) * | 2000-03-23 | 2001-09-27 | Elan Pharmaceuticals, Inc. | Composes et methodes de traitement de la maladie d'alzheimer |
US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
EP1159964B1 (fr) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Utilisation de secrétagogues d'hormones de croissance pour stimuler la motilité gastrointestinale |
US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
EP1666452A2 (fr) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Composés pour le traitement de la maladie d'Alzheimer |
PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
DE60116313T2 (de) | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
SI1368336T1 (sl) * | 2001-02-16 | 2006-10-31 | Allelix Neuroscience Inc | S tiofenom substituirani aminski derivati kot inhibitorji glyt-1 |
CA2440042C (fr) * | 2001-03-05 | 2011-09-27 | Transtech Pharma, Inc. | Derives de carboxamide utilises comme agents therapeutiques |
JP2004523565A (ja) * | 2001-03-05 | 2004-08-05 | トランス テック ファーマ,インコーポレイテッド | 治療因子としてのベンゾイミダゾール誘導体 |
EP1401452A1 (fr) * | 2001-06-27 | 2004-03-31 | Elan Pharmaceuticals, Inc. | Derives de beta-hydroxyamine utiles dans le traitement de la maladie d'alzheimer |
US20070213407A1 (en) * | 2001-06-29 | 2007-09-13 | Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc | Compounds to treat Alzheimer's disease |
SI1471054T1 (sl) * | 2002-01-11 | 2009-12-31 | Daiichi Sankyo Co Ltd | Amino alkoholni derivati ali derivati fosfoniäśne kisline in medicinski sestavki, ki vsebujejo le-te |
US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
MXPA05012350A (es) * | 2003-05-20 | 2006-05-25 | Transtech Pharma Inc | Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma. |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
WO2005027913A1 (fr) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un secretagogue de l'hormone de croissance |
CA2557536C (fr) | 2004-02-24 | 2010-07-13 | Sankyo Company Limited | Compose d'alcool amine |
CA2565324A1 (fr) * | 2004-03-30 | 2005-10-20 | Sapphire Therapeutics, Inc. | Procede de reduction de la proteine c-reactive a l'aide de secretagogues de l'hormone de croissance |
EP1768976B1 (fr) * | 2004-06-29 | 2017-04-26 | Helsinn Healthcare S.A. | Formes cristallines d'acide (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylique 1,2,2-trimethylhydrazide |
ES2388501T3 (es) * | 2004-08-12 | 2012-10-16 | Helsinn Healthcare S.A. | Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal |
EP1942193A4 (fr) | 2005-08-25 | 2010-10-27 | Ube Industries | PROCÉDÉ DE PRODUCTION D ACIDE (S OU R)-a -AMINÉ OPTIQUEMENT ACTIF OU D ESTER D ACIDE (S OU R)-a-AMINÉ OPTIQUEMENT ACTIF |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
ES2558928T3 (es) | 2007-01-31 | 2016-02-09 | Dana-Farber Cancer Institute, Inc. | Péptidos p53 estabilizados y usos de los mismos |
WO2008130464A1 (fr) | 2007-02-09 | 2008-10-30 | Tranzyme Pharma, Inc. | Modulateurs macrocycliques du récepteur de la ghréline et leurs procédés d'utilisation |
EA200970764A1 (ru) * | 2007-02-13 | 2010-04-30 | ХЕЛСИНН ТЕРАПЬЮТИКС (Ю. Эс.), ИНК. | Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста |
BRPI0809366B8 (pt) | 2007-03-28 | 2021-05-25 | Harvard College | polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica |
TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
UA105657C2 (uk) | 2009-02-27 | 2014-06-10 | Хелсінн Терапьютікс (Ю.Ес.), Інк. | Поліпшені способи лікування мігрені на основі анамореліну |
TWI517850B (zh) | 2009-09-30 | 2016-01-21 | Vtv治療有限責任公司 | 經取代之咪唑衍生物及其使用方法 |
CA2807685C (fr) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | Macrocycle peptidomimetique derive de p53 |
TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
CN108912211A (zh) | 2012-02-15 | 2018-11-30 | 爱勒让治疗公司 | 三唑交联的和硫醚交联的拟肽大环化合物 |
US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
WO2014071241A1 (fr) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
EP3197478A4 (fr) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques et leurs utilisations |
KR20170129879A (ko) | 2015-03-20 | 2017-11-27 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
EP3916817B1 (fr) | 2016-02-09 | 2024-09-18 | Lumeova, Inc | Dispositifs et systèmes de communication à haute vitesse, sans fil, à très large bande |
WO2019190822A1 (fr) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Formes cristallines de [3-(4- {2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine |
WO2019190823A1 (fr) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Sels pharmaceutiquement acceptables de [3-(4- {2-butyl-1-[4-(4-chlorophénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine |
WO2020076668A1 (fr) | 2018-10-10 | 2020-04-16 | Vtv Therapeutics Llc | Métabolites de [3-(4-{2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl}-phénoxy)-propyl]-diéthyl-amine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT736039E (pt) * | 1993-12-23 | 2001-04-30 | Novo Nordisk As | Compostos com propriedades para liberar a hormona de crescimento |
IL116923A (en) * | 1995-01-27 | 2000-09-28 | Novo Nordisk As | Compounds with growth hormone releasing properties and pharmaceutical compositions containing them |
ES2323159T3 (es) * | 1995-12-22 | 2009-07-07 | Novo Nordisk A/S | Compuestos con propiedades de liberacion de la hormona del crecimiento. |
-
1997
- 1997-07-17 AT AT97930368T patent/ATE218537T1/de not_active IP Right Cessation
- 1997-07-17 WO PCT/DK1997/000314 patent/WO1998003473A1/fr active IP Right Grant
- 1997-07-17 AT AT01123155T patent/ATE304528T1/de not_active IP Right Cessation
- 1997-07-17 AU AU34346/97A patent/AU3434697A/en not_active Abandoned
- 1997-07-17 EP EP97930368A patent/EP0923539B1/fr not_active Expired - Lifetime
- 1997-07-17 US US08/896,550 patent/US5922770A/en not_active Expired - Lifetime
- 1997-07-17 DE DE69713109T patent/DE69713109T2/de not_active Expired - Lifetime
- 1997-07-17 DE DE69734215T patent/DE69734215T2/de not_active Expired - Lifetime
- 1997-07-17 JP JP50646598A patent/JP4425992B2/ja not_active Expired - Lifetime
- 1997-07-17 EP EP01123155A patent/EP1184370B1/fr not_active Expired - Lifetime
- 1997-07-18 ZA ZA9706371A patent/ZA976371B/xx unknown
-
1999
- 1999-03-17 US US09/270,862 patent/US6127354A/en not_active Expired - Lifetime
-
2000
- 2000-07-19 US US09/619,227 patent/US6274584B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ZA976371B (en) | 1998-01-22 |
DE69734215T2 (de) | 2006-06-29 |
JP4425992B2 (ja) | 2010-03-03 |
DE69713109D1 (de) | 2002-07-11 |
WO1998003473A1 (fr) | 1998-01-29 |
EP1184370A2 (fr) | 2002-03-06 |
ATE218537T1 (de) | 2002-06-15 |
US5922770A (en) | 1999-07-13 |
EP1184370A3 (fr) | 2002-03-27 |
DE69713109T2 (de) | 2003-01-02 |
US6127354A (en) | 2000-10-03 |
JP2000515517A (ja) | 2000-11-21 |
EP1184370B1 (fr) | 2005-09-14 |
EP0923539B1 (fr) | 2002-06-05 |
US6274584B1 (en) | 2001-08-14 |
EP0923539A1 (fr) | 1999-06-23 |
AU3434697A (en) | 1998-02-10 |
DE69734215D1 (de) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE304528T1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
MY113488A (en) | Compounds with growth hormone releasing properties | |
RU94016393A (ru) | Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения | |
ATE69376T1 (de) | Haarwuchsmittel. | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
DE69333607D1 (de) | Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen | |
ATE271874T1 (de) | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen | |
DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
SE9401406L (sv) | Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma | |
IT8619055A0 (it) | Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria. | |
DK0562705T3 (da) | Anvendelse af L-deprenyl til fremstilling af et lægemiddel til behandling af Cushings sygdom | |
DE69716223D1 (de) | Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung | |
ATE316379T1 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
GR3019774T3 (en) | Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system | |
DE69007065D1 (de) | Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten. | |
GR3032224T3 (en) | Therapeutic agent for threatened abortion. | |
YU60199A (sh) | Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji | |
NO166280C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n'-disubstituerte ureaer. | |
FI102810B1 (fi) | Aine eläimen ihon käsittelyyn | |
RU2001113054A (ru) | Способ лечения послеродового острого гнойно-катарального эндометрита коров | |
AP1629A (en) | Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes. | |
WO2001068693A8 (fr) | Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide | |
RU2001123759A (ru) | Способ лечения одонтогенного остеомиелита, осложненного флегмоной | |
FI935575A7 (fi) | 3-(kinolin-6-yylimetyyli)-4H-imidatsol-4-onijohdannaisia, menetelmä niiden valmistamiseksi ja niiden terapeuttinen käyttö |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |